I-Mab Announces Upcoming Participation at October Conferences


    SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October. Details of the conferences are as follows:

    J.P. Morgan Global Healthcare Conference

    One-on-one and small group meetings: October 12-13, 2021

    Location: Ritz-Carlton Hotel, Shanghai

    Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, Mr. Tianyi Zhang, Executive Director Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

    For more information, please contact your J.P. Morgan representative.

    Jefferies China Biotech Summit (Virtual)

    One-on-one and small group meetings: October 26, 2021

    Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, Mr. Tianyi Zhang, Executive Director Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

    For more information, please contact your Jefferies representative.

    About I-Mab

    I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedInTwitter and WeChat.

    For more information, please contact:

    I-Mab

    Jielun Zhu, Chief Financial Officer
    E-mail: jielun.zhu@i-mabbiopharma.com
    Office line: +86 21 6057 8000

    Gigi Feng, Chief Communications Officer
    E-mail: gigi.feng@i-mabbiopharma.com
    Office line: +86 21 6057 5709

    Investor Inquiries:

    The Piacente Group, Inc.
    Emilie Wu
    E-mail: emilie@thepiacentegroup.com
    Office line: + 86 21 6039 8363

    Related Links :

    http://www.i-mabbiopharma.com

    PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a Cision company.

    RELATED NEWS